Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Rating Lowered by Berenberg Bank

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was downgraded by investment analysts at Berenberg Bank from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Marketbeat reports.

FMS has been the subject of several other reports. Citigroup reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. Zacks Research raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. BNP Paribas Exane cut shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective for the company. in a report on Tuesday, July 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 4th. Finally, Truist Financial set a $25.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, August 5th. Seven investment analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $23.67.

Fresenius Medical Care AG & Co. KGaA Stock Up 1.2%

NYSE:FMS opened at $22.95 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.43. The stock’s fifty day moving average is $23.46 and its two-hundred day moving average is $22.95. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $20.02 and a 52 week high of $27.64. The stock has a market capitalization of $12.33 billion, a price-to-earnings ratio of 11.89, a price-to-earnings-growth ratio of 4.21 and a beta of 0.76.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings data on Monday, August 3rd. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.04. The business had revenue of $5.55 billion during the quarter, compared to analysts’ expectations of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. Research analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.25 EPS for the current year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Allworth Financial LP grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% during the second quarter. Allworth Financial LP now owns 3,552 shares of the company’s stock worth $80,000 after purchasing an additional 850 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA in the second quarter valued at $91,000. EverSource Wealth Advisors LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 50.3% in the first quarter. EverSource Wealth Advisors LLC now owns 4,135 shares of the company’s stock valued at $93,000 after buying an additional 1,383 shares in the last quarter. Parallel Advisors LLC lifted its holdings in Fresenius Medical Care AG & Co. KGaA by 27.9% during the 1st quarter. Parallel Advisors LLC now owns 4,632 shares of the company’s stock worth $104,000 after buying an additional 1,011 shares during the last quarter. Finally, Kathmere Capital Management LLC purchased a new stake in Fresenius Medical Care AG & Co. KGaA during the 1st quarter worth about $219,000. 8.37% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on kidney disease and dialysis services. The company provides hemodialysis and peritoneal dialysis treatments through a global network of outpatient dialysis clinics and supports patients with related care and medical services.

In addition to operating dialysis centers, Fresenius Medical Care develops and manufactures products used in renal care. Its portfolio includes dialysis machines, dialyzers, bloodlines, concentrates, solutions, pharmaceuticals and other disposable supplies.